India’s first intranasal Covid vaccine by Bharat Biotech received approval from the Drug Controller General of India (DCGI) for primary immunization against the injection for people above the age of 18. It is India’s first nasal vaccine for COVID-19. The Union Minister of Health and Family Welfare Mansukh Mandaviya termed the vaccine a ‘Big Boost’ to India’s fight against COVID-19.
Bank Maha Pack includes Live Batches, Test Series, Video Lectures & eBooks
Bharat Biotech International Limited (BBIL), is a global leader in vaccine innovation and developer of vaccines for infectious diseases. The BBIL announced that the development of the Intranasal COVID vaccine (BBV154), has been approved for restricted use in an emergency. The iNCOVACC, is a recombinant replication-deficient adenovirus vectored vaccine with a pre-fusion stabilized spike protein. This vaccine was evaluated in phases I, II, and III, clinical trials with successful results. The vaccine was formulated to allow Intranasal delivery through nasal drops. It is designed to be cost-effective in low and middle-income countries.
Goa is a small state on the western coast of India, famous for its beaches,…
Every year, people around the world search for words that show what interests them the…
The Hurun Rich List 2025 has once again highlighted India’s dynamic startup and business ecosystem.…
India’s innovation ecosystem has received global recognition as an Indian satellite internet concept emerged as…
India’s fiscal position showed resilience in the current financial year as net direct tax collections…
Recently, the Union Minister informed the Rajya Sabha about the progress and impact of the…